ONC201 in Gliomas

ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that is able to penetrate the blood-brain-barrier effectively. ONC201 engages proven anti-cancer pathways that lead to apoptosis in cancer cells. Oncoceutics has completed Phase I studies with ONC201 in solid tumors and has additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies ongoing.

Based on clinical results indicating that ONC201 may be effective against gliomas with the H3 K27M mutation, Oncoceutics has launched Phase II clinical trials targeting H3 K27M-mutant gliomas.

Objective Response in Patient with Recurrent Glioblastoma after 12 Cycles of ONC201 Therapy (36 Weeks)

Source: Arrillaga-Romany, et al., A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma”, Oncotarget. 2017; 8:79298-79304. https://doi.org/10.18632/oncotarget.17837